ras peptide cancer vaccine
ras peptide cancer vaccine is a pharmaceutical drug with 7 clinical trials. Historical success rate of 100.0%.
Success Metrics
Based on 7 completed trials
Phase Distribution
Phase Distribution
5
Early Stage
2
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
100.0%
7 of 7 finished
0.0%
0 ended early
0
trials recruiting
7
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Vaccine Therapy in Treating Patients With Colon, Pancreatic, or Lung Cancer
Vaccine Therapy Plus QS21 in Treating Patients With Advanced Pancreatic or Colorectal Cancer
Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer
Vaccine Therapy and Biological Therapy in Treating Patients With Advanced Cancer
Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors
Clinical Trials (7)
Vaccine Therapy in Treating Patients With Colon, Pancreatic, or Lung Cancer
Vaccine Therapy Plus QS21 in Treating Patients With Advanced Pancreatic or Colorectal Cancer
Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer
Vaccine Therapy and Biological Therapy in Treating Patients With Advanced Cancer
Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors
Vaccine Therapy and Sargramostim in Treating Patients With Non-small Cell Lung Cancer
Vaccine Therapy in Treating Patients With Myelodysplastic Syndrome
All 7 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 7